How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Ultra-sensitive Cytokine Detection from Chimera Biotec

Organization name

Chimera Biotec


Ultra-Sensitive Cytokine Detection

Biomarker for inflammatory diseases like cytokines are a challenging target for ligand binding assays. A major goal in current drug development includes specific screening of individuals based on there citokine baseline levels. Chimera Biotec offers ultra-sensitive immunoassay development based on the proprietary Imperacer (Immuno-PCR) platform. Biomarker quantification in the sub pg/ml concentration level becomes possible.


Around 70 per cent of failed clinical trials are predominantly related to

  • unknown endogenous baseline level of target cytokine
  • undetectable drug-target-complex formation
  • limited data in drug efficacy testing with most commonly used ligand-binding technologies


The success of future clinical trials can be significantly increased with more precise and reliable target quantification

  • Determine baseline cytokine levels in healthy control individuals
  • Quantify biomarker concentrations in diseased population and generate data regarding a cut off point
  • detect anti-cytikine drug efficacy in complex formation with biomarker target
  • analyse change in biomarker concentration mediated by applied drug dose

Our Offer

Chimera Biotec offers customized immunoassay developments in the basis of the immunoPCR technology Imperacer®. The ultra sensitivity of the Imperacer technology enables biomarker analysis along the entire study course.

Please contact us if you would like to know more about the Imperacer® technology. We will be happy to assist you with your cytokine detection challenge.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries